Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Completed · Phase 1

Conditions studied: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

In brief

The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.

Key facts

Study ID
NCT07074327
Run by
Vertex Pharmaceuticals Incorporated
People needed
74
Starts
2025-07-11
Expected to finish
2026-02-27
Last updated by the study team
2026-03-30

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.